Integrated Report

Roundtable Discussion
with Directors

Navigating Change
and Expectations
for Growth at
the JT Group

Front row, from left

Outside Director

Masato Kitera

Chairman of the Board

Shigeaki Okamoto

Outside Director

Yukiko Uchida

Back row, from left

Deputy Chairman of the Board

Masamichi Terabatake

Outside Director

Kenji Asakura

Fiscal year 2025 marked a period of significant change for the JT Group's management, including a transition in leadership and changes to the business portfolio. The Directors discussed key topics of interest raised through dialogue between Outside Directors and institutional investors. Presented below are excerpts from those discussions.

How does the Board of Directors view the JT Group's business portfolio, and what discussions are being held to enhance corporate value?

Transfer of the pharmaceutical business

TerabatakeIn fiscal year 2025, we made the bold decision to transfer the pharmaceutical business. The business had long contributed to the JT Group's profits through an integrated value chain together with Torii Pharmaceutical Co., Ltd. In recent years, however, it had faced growing uncertainty over its medium- to long-term growth potential within the Group due to factors such as the increasing difficulty of innovative drug discovery, intensifying global competition, and limitations on business activities associated with our position as a company centered on the tobacco business.
At the same time, we believed that, in order to further develop the drug discovery capabilities and expertise cultivated within the JT Group into the future, the business should operate under a pharmaceutical company that recognizes the value of both the pharmaceutical business and Torii Pharmaceutical Co., Ltd., while placing a strong focus on innovative drug discovery. Following extensive discussions at the Board of Directors, we concluded that transferring the business to Shionogi & Co., Ltd., a pharmaceutical company with research and development at its core, was the best course of action.
As part of our corporate responsibility, we believe it is important to provide an environment in which the drug discovery capabilities we have built, together with the people supporting them, can continue to fully demonstrate their expertise. We also believe this will help foster and maintain the trust of our stakeholders. From this perspective, we view the transfer of the pharmaceutical business as a decision that will contribute to enhancing the JT Group's corporate value over the medium- to long-term.

In 2025, JT appointed a new president for the first time in eight years. In making such an important management decision, what issues and considerations were discussed by the Board of Directors and the Advisory Panel on Nomination and Compensation in reaching that decision?

OkamotoAt the JT Group, we continuously work to strengthen both the quality and depth of our pool of executive management candidates by identifying and developing individuals who are capable of advancing the Group's management principle, the 4S model, and contributing to enhancement of corporate value over the medium- to long-term. With respect to the decision-making process, candidate proposals formulated by the president are deliberated by the Advisory Panel on Nomination and Compensation, with advice provided by the Outside Directors, before a final decision is made by the Board of Directors.

Governance across the JT Group's global operations is also an area of strong interest among institutional investors. How does the Board of Directors view governance across the Group as a whole?

Current state of global governance

TerabatakeSince January 2022, we have unified the operating structures of the domestic and international tobacco businesses under a One Team structure in order to strengthen the management of the tobacco business.
The headquarters functions for the tobacco business, including the Japan market, were integrated into JTI in Switzerland, which serves as the headquarters for the international tobacco business. In addition to the R&D functions that had already been integrated, reporting lines for functions related to the tobacco business, including marketing, sales, manufacturing, leaf procurement, and quality assurance, have also been globally integrated.
At the same time, strengthening governance in line with the One Team structure required us to establish both a robust foundational system and an organizational structure designed to minimize the risk of misconduct. Over the course of two years, we fully integrated the Enterprise Resource Planning (ERP) systems used in Japan and overseas in January 2024. Because we now operate a single global ERP instance and use common operational guidelines worldwide as the basis for decision-making, any decisions made overseas can be fully monitored by JT headquarters in Tokyo. In this way, our governance framework has also been strengthened from systems and infrastructure perspectives.

How do you intend to leverage your skills and experience to contribute to the enhancement of corporate value and the JT Group's sustainable growth?

UchidaThe JT Group is a company centered on the tobacco business. However, I think it would be unfortunate if the Group's business activities were viewed in purely binary terms as either personally relevant or irrelevant depending solely on whether someone smokes. I am deeply interested in how the diverse concept of "fulfilling moments" will take shape, as well as how the JT Group will connect that concept to its business activities and articulate a broader vision for the future.
As a Director, I hope to contribute from my own perspective by offering viewpoints and raising questions that may be difficult to recognize from within the organization alone, while supporting the process of cultivating and nurturing the seeds of "fulfilling moments."

Integrated Report

2026